Zevra shares not reflecting Miplyffa opportunity, says H.C. Wainwright

H.C. Wainwright reiterates a Buy rating on Zevra Therapeutics (ZVRA) with a $26 price target after the company signed an exclusive expanded access distribution agreement with Uniphar (UPR). The deal adds new territories to Zevra’s current expanded access program for Miplyffa for Niemann-Pick disease type C patients, the analyst tells investors in a research note. H.C. Wainwright believes the expanded opportunity for Miplyffa is currently not priced into the stock or reflected in consensus expectations.